SCHEMBL6098735

SCHEMBL6098735

CC(=O)n1cc(C2=CC(=O)NC2=O)c2cc(OCc3ccccc3)ccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.48
MAOB P27338 7/20 0.44
MAOA P21397 3/20 0.44
CREBBP Q92793 1/20 0.42
SRD5A2 P31213 1/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
LTB4R Q15722 3/20 0.40
LTB4R2 Q9NPC1 2/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6100670 0.89 MAOB (0.43) MAOBMAOACREBBPSRD5A2HTR6
SCHEMBL6098654 0.84 NPC1 (0.41) MAOBMAOACREBBPNPC1RAB9A
SCHEMBL6099369 0.84 KDM4E (0.42) MAOBMAOANPC1RAB9APPARG
SCHEMBL6799799 0.84 PPARG (0.41) MAOBMAOASRD5A2MEN1NPC1
SCHEMBL6098773 0.84 MAOB (0.37) BAZ2BMAOBMAOASRD5A2PPARG
SCHEMBL6098776 0.83 LTA4H (0.39) BAZ2BMAOBMAOASRD5A2MEN1
SCHEMBL6098592 0.83 PPARD (0.48) MAOBMAOAPPARGPPARDPPARA
SCHEMBL6097466 0.82 MAOB (0.44) MAOBMAOASRD5A2MEN1NPC1
SCHEMBL6099511 0.79 MAOB (0.41) MAOBMAOAMEN1NPC1RAB9A
SCHEMBL6099154 0.79 HTR6 (0.52) MAOBMAOAMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129250-B2 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2006-10-31 US disclosed
US-20040220202-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-11-04 US disclosed
US-20040102467-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-05-27 US disclosed
EP-1283836-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS Aegera Therapeutics Inc. (CA) 2003-02-19 EP disclosed
WO-2001087887-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS AEGERA THERAPEUTICS INC. (CA) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220202-A1 Neuroprotective and anti-proliferative compounds NLN, MKI67, BDNF BAZ2B 928/4885MAOB 859/4885MAOA 1148/4885
US-20040102467-A1 Neuroprotective and anti-proliferative compounds MKI67, NLN, BDNF BAZ2B 1019/4885MAOB 895/4885MAOA 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.